Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Apr;40(4):461-476.
doi: 10.1007/s40273-021-01099-2. Epub 2022 Jan 30.

Cost-Effectiveness Analysis of Herpes Zoster Vaccination in 50- to 85-Year-Old Immunocompetent Belgian Cohorts: A Comparison between No Vaccination, the Adjuvanted Subunit Vaccine, and Live-Attenuated Vaccine

Zoë Pieters  1 , Benson Ogunjimi  2   3   4   5 , Philippe Beutels  2 , Joke Bilcke  6
Affiliations

Cost-Effectiveness Analysis of Herpes Zoster Vaccination in 50- to 85-Year-Old Immunocompetent Belgian Cohorts: A Comparison between No Vaccination, the Adjuvanted Subunit Vaccine, and Live-Attenuated Vaccine

Zoë Pieters et al. Pharmacoeconomics. 2022 Apr.

Abstract

Background: A new adjuvanted subunit vaccine (HZ/su), with higher vaccine efficacy than live-attenuated vaccine (ZVL), has been licensed in Europe since March 2018. Therefore, Belgian decision-makers might need to re-assess their recommendations for vaccination against herpes zoster (HZ).

Methods: We conducted a cost-effectiveness analysis, using a Markov decision tree, of vaccinating 50- to 85-year-old immunocompetent Belgian cohorts with no vaccination, HZ/su, ZVL, and ZVL with booster after 10 years. Due to the uncertainty in vaccine waning of HZ/su vaccine beyond 4 years, we used a logarithmic and 1-minus-exponential function to model respectively a long and short duration of protection. We used a lifetime time horizon and implemented the health care payer perspective throughout the analysis.

Results: HZ/su had the greatest impact in avoiding health and economic burden. However, it would never become cost-effective at a willingness-to-pay threshold of €40,000 per quality-adjusted life year (QALY) gained at its market price set by the manufacturer in the USA. Depending on the waning function assumed for HZ/su, the price per dose needs to drop 60% or 83% such that vaccination with HZ/su, assuming respectively a long or short duration of protection, would become cost-effective in 50- and 80-year-old individuals. At €40,000 per QALY gained, ZVL or ZVL with booster was never found cost-effective compared with HZ/su, even if only administration cost was considered.

Conclusion: HZ/su is cost-effective in the 50-year-old age cohort at the unofficial Belgian threshold of €40,000 per QALY gained, if its price drops to €55.40 per dose. This result is, however, very sensitive to the assumed duration of protection of the vaccine, and the assumed severity and QALY loss associated with HZ and post-herpetic neuralgia (PHN).

PubMed Disclaimer

Comment in

References

    1. Hope-Simpson RE. The nature of herpes zoster: a long-term study and a new hypothesis. J R Soc Med. 1965;58:9–20. https://doi.org/10.1177/003591576505800106 . - DOI
    1. Scott FT, Johnson RW, Leedham-Green M, Davies E, Edmunds WJ, et al. The burden of herpes zoster: a prospective population based study. Vaccine. 2006;24:1308–14. https://doi.org/10.1016/j.vaccine.2005.09.026 . - DOI - PubMed
    1. Bilcke J, Ogunjimi B, Marais C, De Smet F, Callens M, et al. The health and economic burden of chickenpox and herpes zoster in Belgium. Epidemiol Infect. 2012;140:2096–109. https://doi.org/10.1017/S0950268811002640 . - DOI - PubMed
    1. Drolet M, Brisson M, Schmader KE, Levin MJ, Johnson R, et al. The impact of herpes zoster and postherpetic neuralgia on health-related quality of life: a prospective study. CMAJ. 2010;182:1731–6. https://doi.org/10.1503/cmaj.091711 . - DOI - PubMed - PMC
    1. Brisson M, Edmunds WJ, Law B, Gay NJ, Walld R, et al. Epidemiology of varicella zoster virus infection in Canada and the United Kingdom. Epidemiol Infect. 2001;127:305–14. https://doi.org/10.1017/S0950268801005921 . - DOI - PubMed - PMC

Publication types

LinkOut - more resources